Pediatr Crit Care Med:右美托咪啶作为单次连续镇静药物用于无创通气:经典用法、血流动力学影响及戒断反应

2018-01-28 田磊 “罂粟花”微信号

右美托咪定儿科重症监护中的应用正在增加,作为单一镇静药物连续用药其长期作用并没有得到很好描述。本研究的目的是在不存在其他持续镇静情况下,描述长期应用右美托咪定治疗下的血流动力学效应,停用策略,以及戒断的危险因素。

背景与目的:右美托咪定儿科重症监护中的应用正在增加,作为单一镇静药物连续用药其长期作用并没有得到很好描述。本研究的目的是在不存在其他持续镇静情况下,描述长期应用右美托咪定治疗下的血流动力学效应,停用策略,以及戒断的危险因素。

方  法:数据来源于未满18岁被PICU 收入的382名儿童,在不存在其他持续镇静情况下接受右美托咪定镇静无创正压通气超过24小时。本研究中采用右美托咪啶的常用使用方法。中止策略被定义为突然中止右美托咪啶注射液及可乐定直肠用药过渡。

结  果:中位峰值和累积值在四分位数范围内分别为1 μg/kg/h(0.6-1.2 μg/kg/hr)和30 μg/kg (20-50 μg/kg),持续时间中位数为45h(34-66 h)。在达到剂量峰值4小时后,我们观察到心率下降(p<0.01)且心动过缓发生率为28%;收缩压升高(p<0.01),且高血压发生率为33%,低血压发生率2%。在剂量增加阶段,心动过缓和低血压的患病率分别为75%和30%。有336例(88%)患者发生突然用药中断,37(10%)逐渐过渡,9例(2%例)转为可乐定。19例(5%)患者发生戒断反应。戒断的独立危险因素与持续时间相关最大:每12小时的比值比为1.5(1.3-1.7),P值小于0.01。通过包括年龄、中断组、右美托咪定累计量、最大剂量在内的多变量分析,只有累积剂量与10 μg/kg下比值比1.3(1.1-1.5) 保持显着相关性,p值小于0.01。

结  论:右美托咪定在儿童重症监护中用于无创正压通气镇静具有可预见的血流动力学效应,包括心动过缓和高血压。虽然戒断与更高的累积剂量有关,短期直肠可乐定用药可有效地控制治疗这些症状。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-09-05 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1727022, encodeId=31161e27022a0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 05:15:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944142, encodeId=718e19441425f, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Thu Apr 12 01:15:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812056, encodeId=3f9f181205630, content=<a href='/topic/show?id=d7a1891613d' target=_blank style='color:#2F92EE;'>#血流动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89161, encryptionId=d7a1891613d, topicName=血流动力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Feb 28 00:15:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037575, encodeId=de4d203e5758e, content=<a href='/topic/show?id=1add9681548' target=_blank style='color:#2F92EE;'>#镇静药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96815, encryptionId=1add9681548, topicName=镇静药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sat Feb 17 08:15:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638373, encodeId=f21816383e31d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:15:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392006, encodeId=1b7b1392006d8, content=<a href='/topic/show?id=3704891621c' target=_blank style='color:#2F92EE;'>#血流动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89162, encryptionId=3704891621c, topicName=血流动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495701, encodeId=78ce1495e01cb, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608488, encodeId=91651608488a0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 30 01:15:00 CST 2018, time=2018-01-30, status=1, ipAttribution=)]

相关资讯

Exp Ther Med:甲状腺手术患者术后联合使用右美托咪定和氟比洛芬酯的好处

本研究的目的是研究全麻甲状腺手术患者联合使用右美托咪定(Dex)和氟比洛芬酯(FA)对术后镇痛,免疫反应以及认知功能的影响。

J Med Primatol:在异氟烷麻醉中接受双侧输卵管结扎手术的卷尾猴使用利多卡因复合吗啡或右美托咪定对心肺功能的影响

硬膜外麻醉可以减少其他麻醉要求,延长镇痛,并减少副作用。在灵长类动物中,它的使用很少被描述。本实验的目的是评价使用利多卡因与吗啡(MOR)或右美托咪定(DEX)的硬膜外麻醉对心肺影响。

BMC Anesthesiol:右美托咪定或可有效治疗脑缺血损伤

本研究旨在探讨在PC12细胞和原代神经元细胞中右美托咪定(DMED)对缺氧缺糖(OGD)所诱导的脑损伤。研究人员将PC12细胞暴露于OGD以建立缺血模型。使用细胞存活率、凋亡相关蛋白的表达和凋亡来评估OGD诱导的细胞损伤。OGD和DMED治疗后探究氧化应激和神经营养因子的表达。OGD和DMED治疗后探究可能涉及的信号通路,并随后加入抑制剂抑制通路。最后,根据炎症因子和氧化应激的变化研究DMED对初

Exp Ther Med:全麻甲状腺手术患者联合使用右美托咪定和氟比洛芬酯的好处

本研究的目的是研究全麻甲状腺手术患者联合使用右美托咪定(Dex)和氟比洛芬酯(FA)对术后镇痛,免疫反应以及认知功能的影响。

Int J Obstet Anesth:剖宫产中静脉注射右美托咪定及其在乳汁中的浓度

背景与目的:右美托咪定是具有高α2肾上腺素能受体选择性的镇静剂。本研究主要观察静脉注射右美托咪定在椎管内麻醉下进行剖宫产术中的作用及其在初乳中的浓度

Biochem Biophys Res Commun:右美托咪啶通过抑制肺成纤维细胞缝隙连接功能,保护脂多糖诱导的细胞凋亡

背景与目的:α2-肾上腺素受体激动剂右美托咪定对急性肺损伤(ALI)具有保护作用,但其机制还有很多尚不清楚。